Spanish Registry for Embolization of Small Intracranial Aneurysms with Cerecyte Coils (SPAREC) Study Early Experience and Mid-Term Follow-up Results

• Published in: Interventional neuroradiology Vol. 14; no. 4; pp. 375 - 384
• Main Authors: Castro, E., Villoria, F., Castaño, C., Romance, A., Mendez, J.C., Barrena, R., Fortea, F.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.12.2008; Centauro S.r.l
• Subjects: Original; embolization; cerebral aneurysms; endovascular therapy
• ISSN: 1591-0199; 2385-2011
• DOI: 10.1177/159101990801400403

This study aimed to report the results obtained in treating small ruptured and unruptured intracranial aneurysms using Cerecyte coils. A prospective, non-randomized multicenter registry operating in Spain with a reporting period between May 2005 and September 2007. We present clinical and angiographic results for 48 small aneurysms (26 ruptured, five with III cranial nerve paresis, and 17 incidental) that had undergone six months' follow-up. The volumetric percentage occlusion (VPO) achieved and percentage bioactive coils (PBC) used were assessed. No episodes of bleeding occurred during the follow-up period. The technical complication rate was 10.4% (five cases): four thromboembolic complications resolved with medication (8.3%) and one asymptomatic protrusion of a coil into the parent vessel. The clinical complication rate for the procedure was 2.1% (occlusion of the anterior choroidal artery in a ruptured anterior choroidal anaeurysm). Mean VPO was 25.2%. Balloon-assisted technique (BAT) was used in 60.4% of cases. The VPO was higher in the BAT-treated cases (P<0.05). The overall six-month recanalization rate was 16.7% (12.5% minor and 4.2% major recanalizations). Neck size and VPO were unrelated to the recanalization rate. The PBC was higher in cases with progressive Deployment of the device is safe from the standpoint of periprocedural technical and clinical complications. No episodes of hemorrhage were recorded during follow-up. The six-month recanalization and retreatment rates compared favorably with most endovascular platinum and bioactive coil series.